FDA’s Draft Guidance on Leveraging Prior Knowledge for Genome Editing Gene Therapies — The CMC Precedent-Sharing Framework Every GT Program Should Map Before September 1

FDA/CBER’s new draft guidance on leveraging prior knowledge for genome editing gene therapies is the first framework distinguishing which CMC attributes are eligible for platform-based leveraging versus product-specific — comments close September 1, 2026.